Elicera Therapeutics AB - Asset Resilience Ratio

Latest as of December 2022: 0.00%

Elicera Therapeutics AB (ELIC) has an Asset Resilience Ratio of 0.00% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Skr17.00

≈ $1.83 USD Cash + Short-term Investments

Total Assets

Skr46.31 Million

≈ $4.98 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2022)

This chart shows how Elicera Therapeutics AB's Asset Resilience Ratio has changed over time. See ELIC FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Elicera Therapeutics AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ELIC market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr0.00	0%
Short-term Investments	Skr17.00	0.0%
Total Liquid Assets	Skr17.00	0.00%

Asset Resilience Insights

Limited Liquidity: Elicera Therapeutics AB maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Elicera Therapeutics AB Industry Peers by Asset Resilience Ratio

Compare Elicera Therapeutics AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Elicera Therapeutics AB (2022–2022)

The table below shows the annual Asset Resilience Ratio data for Elicera Therapeutics AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	0.00%	Skr17.00 ≈ $1.83	Skr46.31 Million ≈ $4.98 Million	--

pp = percentage points

About Elicera Therapeutics AB

ST:ELIC Sweden Biotechnology

Market Cap

$12.17 Million

Skr113.09 Million SEK

Market Cap Rank

#26518 Global

#571 in Sweden

Share Price

Skr2.33

Change (1 day)

-2.51%

52-Week Range

Skr2.30 - Skr7.90

All Time High

Skr8.56